# AVEO Pharmaceuticals, Inc. clinical trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with AVEO Pharmaceuticals, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AVEO Pharmaceuticals, Inc.: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/aveo-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888075 | Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or... | AVEO Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC), Metastatic Non-small Cell... | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888075) |
| October 3, 2023 | NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck... | AVEO Pharmaceuticals, Inc. | Phase 3 | Recruiting | Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06064877) |
| May 19, 2023 | NCT05865535 | A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Cachexia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05865535) |
| August 3, 2021 | NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | AVEO Pharmaceuticals, Inc. | Phase 3 | Completed | Renal Cell Carcinoma | 343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04987203) |
| March 25, 2021 | NCT04815551 | A Phase 1 Study of AV-380 in Healthy Subjects | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Cachexia | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04815551) |
| September 24, 2019 | NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia | AVEO Pharmaceuticals, Inc. | Phase 2 | Withdrawn | Acute Myeloid Leukemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04100330) |
| May 31, 2019 | NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | AVEO Pharmaceuticals, Inc. | Phase 1/2 | Terminated | Hepatocellular Carcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03970616) |
| May 2, 2017 | NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | AVEO Pharmaceuticals, Inc. | Phase 1/2 | Completed | Carcinoma, Renal Cell | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03136627) |
| December 11, 2015 | NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | AVEO Pharmaceuticals, Inc. | Phase 3 | Completed | Carcinoma, Renal Cell | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02627963) |
| December 17, 2014 | NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated... | AVEO Pharmaceuticals, Inc. | Phase 2 | Terminated | Non-small Cell Lung Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02318368) |
| March 18, 2014 | NCT02090127 | Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient | AVEO Pharmaceuticals, Inc. | Not applicable | No longer available | Mullerian Mixed Tumor of Ovary | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02090127) |
| December 10, 2012 | NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | AVEO Pharmaceuticals, Inc. | Phase 2 | Terminated | Triple Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01745367) |
| August 28, 2012 | NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC | AVEO Pharmaceuticals, Inc. | Phase 2 | Terminated | Metastatic Renal Cell Carcinoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01673386) |
| June 28, 2012 | NCT01631097 | A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Hepatic Impairment | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01631097) |
| May 23, 2012 | NCT01603979 | A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Solid Tumors | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01603979) |
| November 23, 2011 | NCT01478594 | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | AVEO Pharmaceuticals, Inc. | Phase 2 | Completed | Colorectal Cancer | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01478594) |
| June 9, 2011 | NCT01369433 | A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols | AVEO Pharmaceuticals, Inc. | Not applicable | Terminated | Solid Tumors | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01369433) |
| June 2, 2011 | NCT01363804 | A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01363804) |
| June 2, 2011 | NCT01363778 | A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01363778) |
| March 16, 2011 | NCT01316848 | A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Food Effect of Tivozanib in Health Subjects | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01316848) |
| March 2, 2011 | NCT01306630 | A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01306630) |
| February 16, 2011 | NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | AVEO Pharmaceuticals, Inc. | Phase 2 | Completed | Renal Cell Carcinoma | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01297244) |
| September 29, 2010 | NCT01210846 | A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With... | AVEO Pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Solid Tumors | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01210846) |
| February 25, 2010 | NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol... | AVEO Pharmaceuticals, Inc. | Phase 3 | Completed | Advanced Renal Cell Carcinoma | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01076010) |
| December 25, 2009 | NCT01039948 | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | AVEO Pharmaceuticals, Inc. | Phase 1/2 | Completed | Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer, Respiratory Tract Neoplasms | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01039948) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 3 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Not applicable | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 25 |
| Terminated | 6 |
| Withdrawn | 1 |
| No longer available | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Renal Cell | 7 |
| Neoplasms | 6 |
| Colorectal Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Cachexia | 3 |
| Neoplasms by Histologic Type | 2 |
| Breast Neoplasms | 2 |
| Neoplasms by Site | 2 |
| Neoplasm Metastasis | 2 |
| Lymphoma | 1 |
| Multiple Myeloma | 1 |
| Neoplasms, Plasma Cell | 1 |
| Lymphoproliferative Disorders | 1 |
| Lymphatic Diseases | 1 |
| Immunoproliferative Disorders | 1 |
| Vascular Diseases | 1 |
| Cardiovascular Diseases | 1 |
| Paraproteinemias | 1 |
| Blood Protein Disorders | 1 |
| Hematologic Diseases | 1 |
| Hemorrhagic Disorders | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Carcinoma, Hepatocellular | 1 |
| Lung Neoplasms | 1 |
| Respiratory Tract Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Cosmetic surgery practices in the United States](https://specstream.ai/data/businesses/cosmetic-surgery-practices/united-states)
- [European restaurants in the United States](https://specstream.ai/data/businesses/european-restaurants/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
